Drugmaker Parabilis Raises $745 Million in US IPO, Placement

Parabilis Medicines Inc., a clinical-stage cancer drug developer, raised nearly $745 million through an upsized US initial public offering and a private placement. The IPO priced at $20 per share, which was above its marketed range, raising $670 million. This financial milestone allows the company to secure significant capital for its operations. The total funding combines the results of the public offering and the strategic private placement to support its ongoing development of cancer treatments.